Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Numab has raised $54.9M in total funding. The most recent round was Series C. The last funding was announced in January 2025.
Numab's investors include BlackRock, Mitsubishi UFJ Capital, Cormorant Asset Management, RTW Investments, Novo Holdings.
Numab is headquartered in Wadenswil, Switzerland.
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Numab is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Numab — Funding & Investors." VCBacked, January 9, 2025, https://www.vcbacked.co/company/numab. Accessed September 3, 2026.
VCBacked. (2025). Numab — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/numab
{{cite web |title=Numab — Funding & Investors |url=https://www.vcbacked.co/company/numab |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated